Abstract Search

ea0056gp178 | Parathyroid | ECE2018

The global, prospective, observational PARADIGHM^™ registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care

Clarke Bart L , Rejnmark Lars , Brandi Maria Luisa , Germak John , Hahner Stefanie , Houillier Pascal , Kampe Olle , Kasperk Christian , Khan Aliya , Levine Michael A , Mannstadt Michael , Piccolo Rebecca , Shoback Dolores M , Vokes Tamara J , Gittoes Neil

PARADIGHM, a global, prospective, observational registry of patients with chronic hypoparathyroidism (HPT), began enrolment in 2013 to collect data on the natural history of chronic HPT (ClinicalTrials.gov NCT01922440). Since initiation, recombinant human PTH, rhPTH(1-84), has been approved in the United States and Europe as an adjunctive treatment for adult patients with HPT. The protocol for the registry (now a European Medicines Agencydesignated postm...

0 shares

Endocrine Abstracts

The global, prospective, observational PARADIGHM^™ registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care

BiosciAbstracts

Endocrine Abstracts

The global, prospective, observational PARADIGHM™ registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care

BiosciAbstracts

The global, prospective, observational PARADIGHM^™ registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care